_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Welcome to I.ON, the on-demand digital immunology programme designed to provide rheumatologists, dermatologists, immunologists and allergists treating PsO, chronic spontaneous urticaria, psoriatic arthritis and axial spondyloarthritis with first-class, digital, medical educational content.

 

What is axSpA?

axSpA is mainly characterised by inflammatory back pain, as well as involvement of the spine and sacroiliac joints. It also includes patients with:

  • definite radiographic sacroiliitis observed on x-ray and meeting the modified New York (mNY) criteria, classified as having ankylosing spondylitis (AS); and
  • patients without definite sacroiliitis detectable by radiography and not meeting mNY criteria, classified as having non-radiographic axSpA (nr-axSpA).1

axSpA is associated with a decrease in quality of life, work productivity and the burden of pain, fatigue and morning stiffness.1

 

axSpA, axial spondyloarthritis; Pso, psoriasis; mNY, modified New York.

 

Reference

  1. Bohn R, et al. Clin Exp Rheumatol 2018;36(2):263–274.
Rate this content: 
No votes yet
UK | October 2021 | 146369
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]